The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
GI Malignancies Debate 2023 - Chicago | Debating the peri-operative use of HER2-directed therapies in non-metastatic gastroesophageal cancer
Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, provides insight into debates surrounding the management of upper GI malignancies, notably gastroesophageal and gastric adenocarcinoma, that occurred at the Great Debates and Updates GI Malignancies Debate. Discussion was focused on the peri-operative use of HER2-directed therapies in non-metastatic disease states. Emphasis was placed on whether peri-operative or adjuvant therapy is more appropriate for early-stage HER2-positive cases. HER2-directed therapies such as trastuzumab show a lot of promise but are not presently approved in peri-operative settings. The debate involved review and discussion of data relevant to this issue and went on to consider data specific to first line and locally advanced HER2-positive trials, negative data obtained from a study observing the ineffectiveness of trastuzumab plus chemoradiation, and the higher partial complete response rate observed when HER2-directed agents are used in combination. This interview took place at the Great Debates and Updates GI Malignancies Debate in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
